logo-loader
Polarean Imaging PLC

Polarean Imaging appoints former CFO of cancer therapeutics firm as new finance boss

Charles (Chuck) Osborne, Jr joins the company from oncology group Innocrin Pharmaceuticals and would start the role with immediately

Handshake
Osborne will replace outgoing CFO Bill Patrick, who will take up the post of financial controller at Polarean Inc, the group’s subsidiary

Polarean Imaging Plc (LON:POLX) has appointed the former chief financial officer (CFO) of an oncology therapeutics firm as its new finance boss.

The medical imaging firm said Charles (Chuck) Osborne, Jr, who joins the company from Innocrin Pharmaceuticals Inc, would begin the role with immediate effect and will replace outgoing CFO Bill Patrick, who would take up the post of financial controller at Polarean Inc, the group’s subsidiary.

READ: Polarean Imaging signs deal with University of British Colombia

Prior to his role at Innocrin, Osborne was CFO of anti-infective therapy group Scynexis Inc (NASDAQ:SCYX).

Richard Hullihen, Polarean’s chief executive, said Osborne’s “previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function”.

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago

2 min read